Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archinte.1958.00260170005002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New drug discovery of cardiac anti-arrhythmic drugs: insights in animal models.
Sci Rep
September 2023
MVN University, Palwal, Haryana, India.
Cardiac rhythm regulated by micro-macroscopic structures of heart. Pacemaker abnormalities or disruptions in electrical conduction, lead to arrhythmic disorders may be benign, typical, threatening, ultimately fatal, occurs in clinical practice, patients on digitalis, anaesthesia or acute myocardial infarction. Both traditional and genetic animal models are: In-vitro: Isolated ventricular Myocytes, Guinea pig papillary muscles, Patch-Clamp Experiments, Porcine Atrial Myocytes, Guinea pig ventricular myocytes, Guinea pig papillary muscle: action potential and refractory period, Langendorff technique, Arrhythmia by acetylcholine or potassium.
View Article and Find Full Text PDFWhither digitalis? What we can still learn from cardiotonic steroids about heart failure and hypertension.
Am J Physiol Heart Circ Physiol
December 2022
Brain and Heart Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Cloning of the "Na pump" (Na,K-ATPase or NKA) and identification of a circulating ligand, endogenous ouabain (EO), a cardiotonic steroid (CTS), triggered seminal discoveries regarding EO and its NKA receptor in cardiovascular function and the pathophysiology of heart failure (HF) and hypertension. Cardiotonic digitalis preparations were a preferred treatment for HF for two centuries, but digoxin was only marginally effective in a large clinical trial (1997). This led to diminished digoxin use.
View Article and Find Full Text PDFTherapeutic concentrations of digitoxin inhibit endothelial focal adhesion kinase and angiogenesis induced by different growth factors.
Br J Pharmacol
September 2017
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Article Synopsis
- Cardiac glycosides, like digitoxin and digoxin, are traditionally used to treat heart conditions but may also have anti-cancer properties and affect angiogenesis, the formation of new blood vessels.
- Research focused on how these drugs impact the early stages of angiogenesis in human umbilical vein endothelial cells (HUVECs), assessing cell viability, migration, and tube formation.
- Results showed that digitoxin significantly inhibited HUVEC migration and angiogenesis without harming cell viability and suggested its potential as an anti-angiogenic treatment in conditions characterized by abnormal blood vessel growth.
Magnesium sulfate potentiates effect of DigiFab on marinobufagenin-induced Na/K-ATPase inhibition.
Am J Hypertens
November 2013
National Institute on Aging, National Institutes of Health, Baltimore, MD;
Background: Immunoneutralization of elevated circulating levels of endogenous digitalis-like Na/K-ATPase inhibitors (i.e. cardiotonic steroids (CTS)) represents a novel approach in the treatment of preeclampsia (PE).
View Article and Find Full Text PDFTreatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?
Mayo Clin Proc
June 2011
Division of Cardiovascular Medicine, University Hospitals of Cleveland, Case Medical Center, Cleveland, OH, USA.
Heart failure with preserved ejection fraction (HF-PEF) is the clinical syndrome of heart failure associated with normal or near-normal systolic function. Because inhibition of the adrenergic and renin-angiotensin-aldosterone systems has been so effective in the treatment of systolic heart failure, these same therapies have been the subject of recent clinical trials of HF-PEF. In this review, we examine the current evidence about treatment of HF-PEF, with particular emphasis on reviewing the literature for large-scale randomized clinical studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!